FIGURE 7.

Cetuximab-mediated targeting of meditopes to EGFR-overexpressing cancer cells. A, A431 cells were incubated with 5 nm unlabeled cetuximab and 50 nm FITC conjugated peptide (supplemental Table S2, numbers 13 and 15) and analyzed by flow cytometry. Mutations are with respect to Md1. B, concentration-dependent meditope binding. A431 cells were incubated with cetuximab, and the indicated concentrations of cyclic peptides as in A and analyzed by flow cytometry. Data represent mean ± S.D. from duplicate experiments. The control consisted of 500 nm of the respective meditope peptides without cetuximab and represents background binding to the cells due to the hydrophobic nature of the peptide.